share_log

Jiangsu Yuyue Medical Equipment & Supply's (SZSE:002223) Solid Earnings May Rest On Weak Foundations

Jiangsu Yuyue Medical Equipment & Supply's (SZSE:002223) Solid Earnings May Rest On Weak Foundations

江蘇魚躍醫療器材供應有限公司(SZSE:002223)的穩健收益可能建立在基礎薄弱的基礎上
Simply Wall St ·  05/04 21:45

The market for Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.'s (SZSE:002223) stock was strong after it released a healthy earnings report last week. However, we think that shareholders should be cautious as we found some worrying factors underlying the profit.

江蘇魚躍醫療設備用品有限公司的市場s(SZSE:002223)在上週發佈了健康的收益報告後,該股表現強勁。但是,我們認爲股東應謹慎行事,因爲我們發現了利潤背後的一些令人擔憂的因素。

earnings-and-revenue-history
SZSE:002223 Earnings and Revenue History May 5th 2024
SZSE: 002223 收益和收入歷史記錄 2024 年 5 月 5 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

To properly understand Jiangsu Yuyue Medical Equipment & Supply's profit results, we need to consider the CN¥530m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Jiangsu Yuyue Medical Equipment & Supply had a rather significant contribution from unusual items relative to its profit to March 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

爲了正確了解江蘇魚躍醫療器械供應的利潤業績,我們需要考慮不尋常項目帶來的5.3億元人民幣的收益。雖然我們希望看到利潤增加,但當不尋常的物品做出重大貢獻時,我們往往會更加謹慎一些。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。截至2024年3月,江蘇魚躍醫療器械供應的非同尋常項目佔其利潤的相當可觀的貢獻。因此,我們可以推測,這些不尋常的物品使其法定利潤明顯高於原來的水平。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Jiangsu Yuyue Medical Equipment & Supply's Profit Performance

我們對江蘇魚躍醫療器械供應公司利潤表現的看法

As we discussed above, we think the significant positive unusual item makes Jiangsu Yuyue Medical Equipment & Supply's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Jiangsu Yuyue Medical Equipment & Supply's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 29% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Jiangsu Yuyue Medical Equipment & Supply at this point in time. Case in point: We've spotted 2 warning signs for Jiangsu Yuyue Medical Equipment & Supply you should be aware of.

正如我們上面討論的那樣,我們認爲這一重大利好不尋常的項目使江蘇魚躍醫療器械供應的收益無法衡量其潛在盈利能力。因此,我們認爲江蘇魚躍醫療器械供應的潛在盈利能力很可能低於其法定利潤。但是,至少持有人可以從過去三年的每股收益每年增長29%中得到一些安慰。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。因此,儘管收益質量很重要,但考慮江蘇魚躍醫療設備供應公司目前面臨的風險同樣重要。一個很好的例子:我們已經發現了兩個你應該注意的江蘇魚躍醫療設備及用品的警告信號。

Today we've zoomed in on a single data point to better understand the nature of Jiangsu Yuyue Medical Equipment & Supply's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單個數據點,以更好地了解江蘇魚躍醫療設備及供應的利潤性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論